A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANAMORELIN HCL FOR THE TREATMENT OF MALIGNANCY ASSOCIATED WEIGHT LOSS AND ANOREXIA IN ADULT PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

IRB/UVA Tracking #
21243
Contact
Gracie Hockenberry
Contact Email
Contact Phone
1.434.297.7784
Phase
III
Primary purpose
Supportive Care
Cancer PI
Ryan Gentzler
Status
OPEN TO ACCRUAL
Ages
Adult